SIREN : 451260640
JFS PHARMA is a French company founded 22 years ago, specialized in the sector Autres activités de soutien aux entreprises n.c.a.. Based in SAINT-NOM-LA-BRETECHE (78860), this company of category PME shows in 2022 a revenue of 159 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | 158 542 € | 165 879 € | 171 012 € | 149 948 € | 162 672 € | 261 491 € | 248 584 € |
| Net income | 183 087 € | 83 537 € | 132 030 € | 321 337 € | 198 513 € | -3 385 € | -18 705 € | -19 925 € | -57 876 € |
| EBITDA | N/C | N/C | -87 314 € | -6 866 € | -4 000 € | -72 834 € | -5 252 € | -54 814 € | -19 652 € |
| Net margin | N/C | N/C | 83.3% | 193.7% | 116.1% | -2.3% | -11.5% | -7.6% | -23.3% |
In 2024, JFS PHARMA generates positive net income of 183 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
183 087 €
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 97%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
1.386%
97.365%
51.5%
In 2024, the debt ratio of JFS PHARMA (1.39) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of JFS PHARMA (97.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2022, the repayment capacity of JFS PHARMA (0.46) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 2174.83. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
2174.833
In 2024, the liquidity ratio of JFS PHARMA (2174.83) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2022, the interest coverage of JFS PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 131 transactions of similar company sales (all years), the value of JFS PHARMA is estimated at 606 971 € (range 181 581€ - 1 787 086€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 131 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare JFS PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Autres activités de soutien aux entreprises n.c.a.
The revenue of JFS PHARMA in 2022 is 159 k€.
Yes, JFS PHARMA generated a net profit of 183 k€ in 2024.
The headquarters of JFS PHARMA is located in SAINT-NOM-LA-BRETECHE (78860), in the department Yvelines.
The tax return of JFS PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
JFS PHARMA operates in the sector Autres activités de soutien aux entreprises n.c.a. (NAF code 82.99Z). See the 'Sector positioning' section above to compare the company with its competitors.